References

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781

10.1200/jco.2007.12.9593 · 2008 · External reference

Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma

10.3748/wjg.v16.i13.1649 · 2010 · External reference

Preoperative chemoradiotherapy for esophageal or junctional cancer

10.1056/nejmoa1112088 · 2012 · External reference

Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer

10.1016/j.radonc.2005.10.017 · 2005 · External reference

Comparison of heart and coronary artery doses associated with intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy for distal esophageal cancer

10.1016/j.ijrobp.2011.10.053 · 2012 · External reference

Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer

10.1016/j.ijrobp.2012.02.015 · 2012 · External reference

Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer

10.1002/cncr.29857 · 2016 · External reference

Fundamental properties of the delivery of volumetric modulated arc therapy (VMAT) to static patient anatomy

10.1118/1.3453575 · 2010 · External reference

Dosimetric and efficiency comparison of high-dose radiotherapy for esophageal cancer: Volumetric modulated arc therapy versus fixed-field intensity-modulated radiotherapy

10.1111/dote.12144 · 2014 · External reference

Volumetric modulated arc therapy vs. IMRT for the treatment of distal esophageal cancer

10.1016/j.meddos.2010.09.009 · 2011 · External reference

Volumetric modulated arc therapy for lung stereotactic radiation therapy can achieve high local control rates

10.1186/s13014-014-0243-1 · 2014 · External reference

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer: early late toxicity and 3-year clinical outcome

10.1016/j.radonc.2013.08.006 · 2013 · External reference

Clinical outcomes of volume-modulated arc therapy in 205 patients with nasopharyngeal carcinoma: An analysis of survival and treatment toxicities

10.1371/journal.pone.0129679 · 2015 · External reference

Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: A comparison with intensity-modulated radiotherapy techniques

10.1016/j.ijrobp.2010.09.014 · 2011 · External reference

Multi-institutional comparison of volumetric modulated arc therapy vs. intensity-modulated radiation therapy for head-and-neck cancer: A planning study

10.1186/1748-717x-8-26 · 2013 · External reference

Volumetric modulation arc radiotherapy with flattening filter-free beams compared with static gantry IMRT and 3D conformal radiotherapy for advanced esophageal cancer: a feasibility study

10.1016/j.ijrobp.2011.12.041 · 2012 · External reference

The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer

2006 · External reference

Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy

10.1016/j.ijrobp.2007.10.056 · 2008 · External reference

Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma

10.1186/1748-717x-8-75 · 2013 · External reference

Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer

10.1186/1748-717x-9-191 · 2014 · External reference

Multimodality treatment with intensity modulated radiation therapy for esophageal cancer

10.1111/j.1442-2050.2009.01004.x · 2010 · External reference

Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT)

10.1097/01.sla.0000161983.82345.85 · 2005 · External reference

Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival

10.1200/jco.2005.05.017 · 2005 · External reference

Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer

10.1245/s10434-009-0862-1 · 2010 · External reference

A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma

10.1093/annonc/mdh219 · 2004 · External reference

A comparison of multimodal therapy and surgery for esophageal adenocarcinoma

10.1056/nejm199608153350702 · 1996 · External reference

Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113

10.1200/jco.2008.16.6918 · 2008 · External reference

Predictive factors of recurrence in patients with pathological complete response after esophagectomy following neoadjuvant chemoradiotherapy for esophageal cancer: a multicenter study

10.1245/s10434-015-4619-8 · 2015 · External reference

A prospective study of combined therapy in esophageal cancer

1994 · External reference

A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus

10.1002/1097-0142(19940401)73:7<1779::aid-cncr2820730702>3.0.co;2-t · 1994 · External reference

Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus

10.1056/nejm199707173370304 · 1997 · External reference

Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial

10.1016/s1470-2045(05)70288-6 · 2005 · External reference

Predictors of postoperative complications after trimodality therapy for esophageal cancer

10.1016/j.ijrobp.2013.04.006 · 2013 · External reference